# Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection

> **NCT04382937** · PHASE3 · COMPLETED · sponsor: **PharmaEssentia** · enrollment: 222 (actual)

## Conditions studied

- Chronic Hepatitis C Virus Infection

## Interventions

- **DRUG:** P1101 + Ribavirin
- **DRUG:** PEG-Intron + Ribavirin

## Key facts

- **NCT ID:** NCT04382937
- **Lead sponsor:** PharmaEssentia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-12
- **Primary completion:** 2020-07-15
- **Final completion:** 2020-07-15
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2022-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04382937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04382937, "Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04382937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*